I think some likely did end up there after missing an early monoclonal antibody treatment protocol. Those are low-risk, high-effectiveness treatments for early phases and yet do not appear to be a universal standard of care for eligible patients.
(Low risk enough that they’re approved for some confirmed exposure cases prior to developing even a positive PCR test result.)
reply